EMA’s Conflict Of Interest Rules Must Not Limit Access To Experts And Risk Innovation, Warns Industry

The European Medicines Agency has published new policies on handling conflicts of interests for its scientific committee members, experts and management board members.

The EMA has published its updated CoI policy for committee members and experts (Shutterstock)

Strict interpretations of ‘conflict of interest’ (CoI) in the European Medicines Agency policy on handling such concerns among committee members and experts could exacerbate “significant workforce challenges,” particularly as research is becoming increasingly specialized, according to EFPIA, the federation representing the R&D-based pharmaceutical industry in Europe.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval

25 Apr 2025

• By Eliza Slawther

The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.

EMA’s Role In Regulatory Reliance For Post-Approval Changes

25 Apr 2025

• By Vibha Sharma

The European Medicines Agency’s assessments of applications for variations play a key role in supporting international regulatory reliance mechanisms. Companies can aid this by ensuring the scope of their post-approval changes is clear, and notifying the EMA when sharing reports with non-EU regulators.

Semaglutide For MASH Among Raft Of New EU Filings

24 Apr 2025

• By Neena Brizmohun

Novo Nordisk’s application seeking EU marketing approval to use its GLP-1 receptor agonist to treat cirrhotic metabolic dysfunction-associated steatohepatitis is one of 15 new drug filings the European Medicines Agency has started reviewing. Meanwhile, Arrowhead’s filing for its familial chylomicronemia syndrome, plozasiran, is being fast tracked.